Pediatric Neuroblastoma Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Pediatric Neuroblastoma Treatment Market is segmented by Treatment Type (Chemotherapy, Immunotherapy, and Others), Distribution Channel (Hospital Pharmacies and Retail Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

pediatric neuro
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 6.3 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The pediatric neuroblastoma treatment market studied was projected to register a CAGR of nearly 6.3% over the forecast period (2022 - 2027).

The COVID-19 pandemic's emergence had a negative impact on both the global economy and healthcare infrastructure. The pharmaceutical, medical device, and biotech product supply chains have all been impacted due to the worldwide lockdown. On the other side, emphasis has been placed on research and development. The relationship between COVID-19 and cancer has also had an effect on the market's expansion. For instance, children with cancer who are infected with SARS-CoV-2 do not appear to be at increased risk of severe infection compared to the general pediatric population, according to the study "Severity of COVID-19 in children with cancer: Report from the United Kingdom Paediatric Coronavirus Cancer Monitoring Project" published in December 2020. Thus showing that the delivery of the usual care to such patients was only a little interrupted as cacer treatment is one of the nonelective treatment. Furthermore, according to a study published in October 2021 titled "COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study," the majority of paediatric cancer patients do not experience a severe, life-threatening course from SARS-CoV-2 infection. However, there was a significant impact on the market growth due to the supply of common medications used to treat paediatric cancers like neuroblastoma.

The prevalence of neuroblastoma among children, as well as increased research and development and greater public awareness of cancer treatment options, are the main factors driving the market's expansion. According to a National Cancer Institute report from February 2022, there are roughly 1 case of neuroblastoma for every 7,000 live births. Children under the age of 15 experience 10.54 cases per 1 million each year. 90% of patients are under the age of five when they are diagnosed, with a median age of 19 months, and about 37% of patients are diagnosed as newborns. Additionally, the government's increased investments in R&D initiatives to build the paediatric medical infrastructure and the public's growing knowledge of paediatric neuroblastoma therapy are promoting market expansion. For instance, the Rally Foundation for Childhood Cancer Research granted USD 3.4 million in grants to Drs. Miller Huang and Satyaki Sengupta in March 2022 to study the role of the chromosome 17q gain in neuroblastoma, Dr. Muxiang Zhou to find novel MYCN inhibitors of therapy for paediatric neuroblastoma, and other researchers. Thus, during the study period, it is anticipated that the aforementioned drivers will fuel market growth. Though, the high expense of paediatric neuroblastoma treatment remains a significant barrier to market expansion.

Scope of the Report

As per the scope of the report neuroblastoma is cancer that develops from immature nerve cells found in several areas of the body, most commonly arising in and around the adrenal glands. Neuroblastoma is the most common extracranial solid tumor in childhood. The Pediatric Neuroblastoma Treatment Market is segmented by Treatment Type (Chemotherapy, Immunotherapy, and Others), Distribution Channel (Hospital Pharmacies and Retail Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Treatment Type
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Chemotherapy Segment is Dominating the Pediatric Neuroblastoma Treatment Market Over the Forecast Period

Anti-cancer medications are used in chemotherapy, and they are often injected into a vein.

To find and kill cancer cells, the medications enter the bloodstream and circulate throughout the body. Chemotherapy can therefore be used to treat neuroblastoma that has spread to the liver, lungs, lymph nodes, bone marrow, liver, or other organs. The effectiveness of chemotherapeutic medications in the treatment of neuroblastoma as well as the rising incidence of the disease in the pediatric population are primarily responsible for the segment's increasing growth rate. In addition, chemotherapy is the preferred method of treatment to lessen symptoms and decrease the spread of the disease. For better outcomes, it is also used in conjunction with other therapies like radiation therapy or surgery. For instance, in June 2021, a study titled "A Study of N9 Chemotherapy in Children With Neuroblastoma" was started to determine whether N9 is a secure and efficient treatment for kids with neuroblastoma. Cyclophosphamide, topotecan, and vincristine (CTV), ifosfamide, carboplatin, etoposide (ICE), and cyclophosphamide, doxorubicin, and vincristine are the three chemotherapy drug combinations that make up the N9 regimen (CDV). Positive findings from these studies will accelerate the segment's expansion. Depending on their risk group, children with neuroblastoma may or may not get chemotherapy. Chemotherapy is used to treat certain neuroblastoma patients in children, either before or after surgery. Chemotherapy is the primary treatment in a few other situations, particularly when cancer has progressed too far for surgery to completely eradicate it. The market being investigated will also develop as a result of increasing investments in researching the effectiveness of chemotherapy in treating paediatric neuroblastoma. For instance, Jason Shohet, MD, PhD, was awarded a new, two-year USD 300,000 Scholar Hope Grant in January 2022 to concentrate on overcoming drug resistance in chemotherapy treatments for neuroblastoma. Pediatric cancer that affects the peripheral nerve system is fatal. The studied category is therefore anticipated to considerably contribute to the market's expansion as a result of the aforementioned aspects.

Neuroblastoma 5 Year Survival Rates, by Risk Group, in Percentage, United States, 2021

North America Dominates the Market and Expected to do Same Over the Forecast Period.

North America is expected to dominate the overall market, throughout the forecast period. The high frequency of pediatric neuroblastoma in the area and the well-established healthcare infrastructure are some of the main factors responsible for its significant market share. In addition, encouraging government initiatives and a rise in research collaboration numbers are among the factors anticipated to boost market expansion. Due to its pro-health care legislation, large patient population, and developed healthcare market, the United States has the largest share in this region. The American Society of Clinical Oncology (ASCO) said in a February 2022 article that in North America, neuroblastoma affects 700 to 800 children annually between the ages of 0 and 14. Six percent of all childhood malignancies in the US are caused by neuroblastoma. The same source states that children under the age of five account for roughly 90% of neuroblastoma cases. Between 1 and 2 years old is the typical age of diagnosis. Additionally, product approvals in the studies market will broaden the leading competitors' product portfolios and increase effective treatment, which will fuel market expansion. For instance, the FDA of the United States approved the medication naxitamab (Danyelza) in January 2021 for the treatment of people with high-risk neuroblastoma. Researchers at MSK Kids, the paediatric cancer programme at Memorial Sloan Kettering, created this medication. Additionally, growing initiatives by important market participants, including collaborations, mergers, and acquisitions, among others, will also significantly contribute to the market's expansion. For instance, in August 2021, United Therapeutics Corporation entered in a partnership with former NFL player Devon Still and his daughter Leah, a high-risk neuroblastoma survivor, to introduce the educational programme "Braving NeuroBLASToma," which sheds light on the uncommon cancer that affects neuroblasts, which are immature nerve cells. The average age of diagnosis for neuroblastoma is between one and two years old, while it frequently manifests in newborns and kids under the age of five. The industry under study is therefore anticipated to have significant expansion in the area as a result of the aforementioned considerations.

Pediatric Neuroblastoma Market - Growth Rate by Region - Image

Competitive Landscape

The pediatric neuroblastoma treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are United Therapeutics Corporation, APEIRON Biologics AG, Baxter, CELLECTAR BIOSCIENCES, INC, Pfizer, Inc., Bayer AG, MacroGenics, Inc., Sartorius AG. Product launches, partnerships or collaboration, and continuous investment in research and development are some of the strategies companies are adopting to enhance their market share. 

Major Players

  1. Baxter International

  2. United Therapeutics Corporation

  3. APEIRON Biologics AG

  4. Y-mAbs Therapeutics, Inc.


pediat neuro

Recent Development

  • In February 2022, the United States Food and Drug Administration granted a Fast Track Designation (FTD) to the targeted inhibitor alrizomadlin (APG-115) for the treatment of neuroblastoma as a rare pediatric disease (RPD). 
  • In January 2022, SACT-1, a repurposed small molecule drug for the treatment of patients with Neuroblastoma, was given the Orphan Drug Designation by the United States Food and Drug Administration (FDA) Office to Aptorum Group Limited.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Burden Of Pediatric Neuroblastoma Coupled With Increasing R&D

      2. 4.2.2 Rise in Awareness of Available Treatment For Cancer

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost And Side Effects Associated With Cancer Therapy

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - in USD Million)

    1. 5.1 By Treatment Type

      1. 5.1.1 Chemotherpay

      2. 5.1.2 Immunotherapy

      3. 5.1.3 Others

    2. 5.2 Distribution Channel

      1. 5.2.1 Hospital Pharmacies

      2. 5.2.2 Retail Pharmacies

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 United Therapeutics Corporation

      2. 6.1.2 APEIRON Biologics AG

      3. 6.1.3 Baxter International

      4. 6.1.4 Pfizer, Inc.

      5. 6.1.5 Bayer AG

      6. 6.1.6 MacroGenics, Inc.

      7. 6.1.7 Sartorius AG



      10. 6.1.10 Y-mAbs Therapeutics, Inc.

      11. 6.1.11 Amgen

      12. 6.1.12 Eli Lilly and Company

      13. 6.1.13 F. Hoffmann-La Roche Ltd

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Pediatric Neuroblastoma Treatment Market market is studied from 2019 - 2027.

The Global Pediatric Neuroblastoma Treatment Market is growing at a CAGR of 6.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Baxter International, United Therapeutics Corporation, APEIRON Biologics AG, Y-mAbs Therapeutics, Inc. , CELLECTAR BIOSCIENCES, INC. are the major companies operating in Global Pediatric Neuroblastoma Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!